Cannabis for Medical Purposes

CMA POLICY

Cannabis for Medical Purposes

The Canadian Medical Association (CMA) has long recognized the value of cannabis as a medication for treating certain medical conditions. The CMA has been involved in discussions and regulatory processes related to cannabis for medical purposes for many years. However, the legalization of cannabis for recreational use in Canada in 2018 has raised new questions about the appropriate use of cannabis for medical purposes.

First, it is important to recognize that cannabis is a complex and multifaceted drug with a range of medical and non-medical effects. While some studies have suggested that cannabis may have potential therapeutic effects for certain medical conditions, there is still much to be learned about the safety and efficacy of cannabis as a medication.

Second, it is essential to ensure that patients who use cannabis for medical purposes have access to appropriate guidance and support. This includes ensuring that patients have access to qualified health care providers who are knowledgeable about the use of cannabis for medical purposes, as well as access to safe and reliable cannabis products.

The CMA recommends the following actions:

1. Support further research into the potential therapeutic effects of cannabis for medical purposes, including studies that focus on the safety and efficacy of different cannabis products and formulations.
2. Support the development of guidelines and best practices for the safe and effective use of cannabis for medical purposes, including guidelines for patients and health care providers.
3. Support the development of regulatory frameworks that are evidence-based and patient-centered, and that take into account the unique needs and circumstances of patients who use cannabis for medical purposes.

The CMA encourages all stakeholders, including government, healthcare providers, and patients, to work collaboratively to ensure that cannabis is used safely and effectively for medical purposes.
Medication use and seniors (Update 2017)
https://policybase.cma.ca/link/policy10151

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2011-05-28
REPLACES  Medication use and seniors
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

CMA POLICY

MEDICATION USE AND SENIORS

(update 2017)

The Canadian Medical Association recommends that prescribing and monitoring of medications for older people be addressed in the following ways:

1. Medications should be prescribed for each patient’s need, and in consultation with the patient.
2. The patient’s medical history should be reviewed in detail.
3. The patient’s family and caregivers should be involved in the decision-making process.
4. The patient should be encouraged to be active in the decision-making process.
5. The patient should be informed of the potential risks and benefits of each medication.
6. The patient should be encouraged to participate in the decision-making process.
7. The patient should be encouraged to be active in the decision-making process.
8. The patient should be encouraged to participate in the decision-making process.
9. The patient should be encouraged to participate in the decision-making process.
10. The patient should be encouraged to participate in the decision-making process.
CMA’s Submission to the House of Commons Standing Committee on Health: Drug Shortages
https://policybase.cma.ca/link/policy10382

POLICY TYPE        Parliamentary submission
DATE              2012-03-29
TOPICS            Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Presentation to the Senate Standing Committee on Social Affairs, Science and Technology – Prescription Drugs: Clinical Trials and Approval

https://policybase.cma.ca/link/policy10437

POLICY TYPE
Parliamentary submission

DATE
2012-05-09

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology – Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals

https://policybase.cma.ca/link/policy10631

POLICY TYPE
Parliamentary submission

DATE
2012-10-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2012-12-08

TOPICS
Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Position statement on prescription drug shortages in Canada
https://policybase.cma.ca/link/policy10756

POLICY TYPE: Policy document
LAST REVIEWED: 2017-03-04
DATE: 2013-05-25
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health

https://policybase.cma.ca/link/policy11035

**POLICY TYPE**  
Parliamentary submission

**DATE**  
2013-11-27

**TOPICS**  
Pharmaceuticals, prescribing, cannabis, drugs

**Documents**
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations

https://policybase.cma.ca/link/policy11114

POLICY TYPE
Response to consultation

DATE
2014-03-17

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety
https://policybase.cma.ca/link/policy11125

POLICY TYPE          Parliamentary submission
DATE                  2014-03-26
TOPICS                Pharmaceuticals, prescribing, cannabis, drugs

Documents
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase
https://policybase.cma.ca/link/policy11129

POLICY TYPE  Parliamentary submission
DATE  2014-05-15
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
The Health risks and harms associated with the use of marijuana
https://policybase.cma.ca/link/policy11138

POLICY TYPE  Parliamentary submission
DATE  2014-05-27
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-17 An Act to amend the Food and Drugs Act
https://policybase.cma.ca/link/policy11196

POLICY TYPE        Parliamentary submission
DATE               2014-06-11
TOPICS             Pharmaceuticals, prescribing, cannabis, drugs

Documents

Bill C-17 in time, released the Food and Drugs
Act-Amending Operations Act (Health Drugs
Cannabis) Act
Information in the House of Commons Standing
Committee on Health

June 11, 2014

Revised Medicine

Effective population with a more medical marijuana
This provision is critical to the public health policies.
Recommendations.
Proposed amendments to the marihuana for medical purposes regulations
https://policybase.cma.ca/link/policy11293

POLICY TYPE
Response to consultation

DATE
2014-07-11

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Bill C–2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/link/policy11297

POLICY TYPE
Parliamentary submission

DATE
2014-10-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Authorizing Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy11514

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2015-02-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11519

POLICY TYPE  Parliamentary submission
DATE  2015-05-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents